Cited by 874HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 73 of the 83 references it cites were found in a registry or an index.

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Open access

Agus, David B, Akita, Robert W, Fox, William D, Lewis, Gail D, Higgins, Brian, Pisacane, Paul I, Lofgren, Julie A, Tindell, Charles, Evans, Douglas P, Maiese, Krista, Scher, Howard I, Sliwkowski, Mark X·2002·Cancer Cell

DOI 10.1016/s1535-6108(02)00097-1

Open this paper in CoChat — free account Open PDF

Abstract

ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in both low- and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00097-1

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citation
Real time quantitative PCR.Preprint
Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
A novel method for real time quantitative RT-PCR.Preprint
Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617
The EGF receptor family as targets for cancer therapy
Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Show all 83 references

Research works printed but not linked: 6

Agus, 1999, Prostate cancer cell cycle regulators, J. Natl. Cancer Inst., 91, 1869, 10.1093/jnci/91.21.1869 · DOI
Lewis, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin, Cancer Res., 56, 1457
Nagabhushan, 1996, CWR22, Cancer Res., 56, 3042
Pinkas-Kramarski, 1996, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO J., 15, 2452, 10.1002/j.1460-2075.1996.tb00603.x · DOI
Tzahar, 1998, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas, Biochim. Biophys. Acta, 1377, M25
Wainstein, 1994, CWR22, Cancer Res., 54, 6049

Sorted by citations

Items 201–300 of 874

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Jathal, M. K., Chen, L., Mudryj, M. M., & Ghosh, P. (2011) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152211795495643 · Cited by 80
Pseudokinases: Update on Their Functions and Evaluation as New Drug Targets
Byrne, D. P., Foulkes, D. M., & Eyers, P. A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0207 · Cited by 84
Antibodies directed against receptor tyrosine kinases
Fauvel, B., & Yasri, A. (2014) · mAbs · doi:10.4161/mabs.29089 · Cited by 81
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action
Eli, L. D., Strommen, K., Dao-Pick, T., Parry, G., Goodman, L. J., & Winslow, J. W. (2011) · Breast Cancer Research · doi:10.1186/bcr2866 · Cited by 82
Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase
Montgomery, B., Makary, E., Schiffman, K., Vivian Goodell, A., & Disis, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.650.65.2 · Cited by 82
Antibodies as therapeutic agents: vive la renaissance!
Stockwin, L., & Holmes, S. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.7.1133 · Cited by 84
Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 2
Sagar, S. M., Yance, D. R., & Wong, R. K. (2006) · Current Oncology · doi:10.3747/co.v13i3.88 · Cited by 82
Four-in-One Antibodies Have Superior Cancer Inhibitory Activity against EGFR, HER2, HER3, and VEGF through Disruption of HER/MET Crosstalk
Hu, S., Fu, W., Xu, W., Yang, Y., Cruz, M., Berezov, S. D., Jorissen, D., Takeda, H., & Zhu, W. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1670 · Cited by 80
Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers
Gaborit, N., Larbouret, C., Vallaghe, J., Peyrusson, F., Mollévi, C., Lopez‐Crapez, E., Azria, D., Chardès, T., Poul, M., Mathis, G., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.223503 · Cited by 84
Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition
Martin, L. P., & Schilder, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1088 · Cited by 80
Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Dang, C. T., Iyengar, N. M., Datko, F. M., D’Andrea, G. M., Theodoulou, M., Dickler, M. N., Goldfarb, S. B., Lake, D. E., Fasano, J., Fornier, M. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1745 · Cited by 79
Pertuzumab and trastuzumab: the rationale way to synergy
Richard, S., Selle, F., Lotz, J., Khalil, A., Gligorov, J., & Soares, D. G. (2016) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201620150178 · Cited by 77
Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells
Singh, S., & Chakrabarti, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050642 · Cited by 78
Monoclonal Antibody-Based Targeted Therapy in Breast Cancer
Bernard-Marty, C., Lebrun, F., Awada, A. H., & Piccart, M. J. (2006) · Drugs · doi:10.2165/00003495-200666120-00004 · Cited by 79
Parsing ERK Activation Reveals Quantitatively Equivalent Contributions from Epidermal Growth Factor Receptor and HER2 in Human Mammary Epithelial Cells
Hendriks, B. S., Orr, G., Wells, A. H., Wiley, H. S., & Lauffenburger, D. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410491200 · Cited by 78
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Arteaga, C. L., O’Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., & Davidson, N. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0482 · Cited by 79
Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling
Zhang, Q., Park, E., Kani, K., & Landgraf, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200105109 · Cited by 78
State of the art in anti-cancer mAbs
Chiavenna, S. M., Jaworski, J. P., & Vendrell, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-016-0311-y · Cited by 79
Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Collins, D. M., Madden, S. F., Gaynor, N., AlSultan, D., Gal, M. L., Eustace, A. J., Gately, K. A., Hughes, C., Davies, A. M., Mahgoub, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2007 · Cited by 83
Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance
Chung, A. P., Cui, X., Audeh, W., & Giuliano, A. E. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.04.001 · Cited by 77
Minireview: The Molecular and Genomic Basis for Prostate Cancer Health Disparities
Powell, I. J., & Bollig-Fischer, A. B. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1039 · Cited by 76
Molecular approach to breast cancer treatment
Yarden, Y., Baselga, J. M., & Miles, D. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.07.016 · Cited by 77
Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung
Shin, D. H., Lee, D., Hong, D. W., Hong, S. H., Hwang, J.-A., Lee, B. I., You, H. J., Lee, G. K., Kim, I.-H., Lee, Y.-S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11913 · Cited by 78
Internalization, Intracellular Trafficking, Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody
Perera, R. M., Zoncu, R., Johns, T. G., Pypaert, M., Lee, F.-T., Mellman, I., Old, L. J., Toomre, D. K., & Scott, A. M. (2007) · Neoplasia · doi:10.1593/neo.07721 · Cited by 75
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1
Zsebik, B., Citri, A., Isola, J. J., Yarden, Y., Szöllõsi, J., & Vereb, G. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.018 · Cited by 75
Targeting the HER-kinase axis in cancer
Gross, M. E., Shazer, R. L., & Agus, D. B. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.01.005 · Cited by 74
Self-citation
HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches
Colombo, M., Corsi, F., Foschi, D., Mazzantini, E., Mazzucchelli, S., Morasso, C., Occhipinti, E., Polito, L., Prosperi, D., Ronchi, S., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.013 · Cited by 73
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
Watanabe, S., Yonesaka, K., Tanizaki, J., Nonagase, Y., Takegawa, N., Haratani, K., Kawakami, H., Hayashi, H., Takeda, M., Tsurutani, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1995 · Cited by 72
The ErbB2 Signaling Network as a Target for Breast Cancer Therapy
Badache, A., & Gonçalvès, A. (2006) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9009-1 · Cited by 78
Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy
Ding, L. J., Tian, C., Feng, S., Fida, G., Zhang, C., Ma, Y., Ai, G., Achilefu, S. A., & Gu, Y. (2015) · Theranostics · doi:10.7150/thno.10084 · Cited by 73
Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR -Mutant Cells
Zhang, J., Iwanaga, K., Choi, K. C., Wislez, M., Raso, M. G., Wei, W., Wistuba, I. I., & Kurie, J. M. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0014 · Cited by 74
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
Liu, X., Liu, S., Lyu, H., Riker, A. I., Zhang, Y., & Liu, B. (2019) · Biological Procedures Online · doi:10.1186/s12575-019-0093-1 · Cited by 72
Systemic therapy for metastatic HER2-positive breast cancer
Bredin, P., Walshe, J. M., & Denduluri, N. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.008 · Cited by 77
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Friedländer, E., Barok, M., Szöllõsi, J., & Vereb, G. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.12.001 · Cited by 72
Drug-biomarker co-development in oncology – 20 years and counting
Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 75
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer
Cortés, J., Baselga, J. M., Im, Y., Im, S., Pivot, X. B., Ross, G. A., Clark, E., Knott, A., & Swain, S. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt274 · Cited by 71
Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way
Lerdrup, M., Hommelgaard, A. M., Grandal, M. M., & van Deurs, B. (2005) · Journal of Cell Science · doi:10.1242/jcs.02707 · Cited by 71
HER2 and lung cancer
Landi, L. M., & Cappuzzo, F. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.846830 · Cited by 73
Targeted therapy in HER2-positive breast cancer
LI, S. G., & Li, L. (2013) · Biomedical Reports · doi:10.3892/br.2013.95 · Cited by 71
Flow cytometric in situ proximity ligation analyses of protein interactions and post‐translational modification of the epidermal growth factor receptor family
Leuchowius, K., Weibrecht, I., Landegren, U. D., Gedda, L., & Söderberg, O. (2009) · Cytometry Part A · doi:10.1002/cyto.a.20771 · Cited by 71
ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells
Krig, S. R., Miller, J. K., Frietze, S. E., Beckett, L. A., Neve, R. M., Farnham, P., Yaswen, P., & Sweeney, C. A. (2010) · Oncogene · doi:10.1038/onc.2010.289 · Cited by 71
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells
Esparı́s-Ogando, A., Ocaña, A., Barrueco, R. R., Ferreira, L., Borges, J., & Pandiella, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn406 · Cited by 71
Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models
Issa, A., Gill, J. W., Heideman, M. R., Şahin, Ö., Wiemann, S., Dey, J. H., & Hynes, N. E. (2013) · Breast Cancer Research · doi:10.1186/bcr3379 · Cited by 73
Beyond trastuzumab: New treatment options for HER2-positive breast cancer
Saini, K. S., Azim, H. A., Metzger, O., Loi, S., Sotiriou, C. P., de Azambuja, E., & Piccart, M. J. (2011) · The Breast · doi:10.1016/s0960-9776(11)70289-2 · Cited by 71
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
Takai, N., Jain, A., Kawamata, N., Popoviciu, L. M., SAID, J. W., Whittaker, S., Miyakawa, I., Agus, D. B., & Koeffler, H. P. (2005) · Cancer · doi:10.1002/cncr.21533 · Cited by 70
Self-citation
Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin
Yuste, L., Montero, J. C., Esparı́s-Ogando, A., & Pandiella, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4023 · Cited by 69
Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies
Laux, I., Jain, A., Singh, S., & Agus, D. B. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602875 · Cited by 69
Self-citation
Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
Loi, S., Sotiriou, C. P., Haibe‐Kains, B., Lallemand, F., Conus, N. M., Piccart, M. J., Speed, T. P., & McArthur, G. A. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-37 · Cited by 69
Targeting Gβγ Signaling to Inhibit Prostate Tumor Formation and Growth
Bookout, A. L., Finney, A. E., Guo, R., Peppel, K., Koch, W. J., & Daaka, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306276200 · Cited by 68
Present and future evolution of advanced breast cancer therapy
Álvarez, R. H. (2010) · Breast Cancer Research · doi:10.1186/bcr2572 · Cited by 71
PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer
Teschendorff, A. E., Naderi, A., Barbosa‐Morais, N. L., & Caldas, C. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl174 · Cited by 67
Human epidermal receptor-2 expression in prostate cancer.
Calvo, B. F., LEVINE, A. M., Marcos, M., Collins, Q. F., Iacocca, M., Caskey, L. S., Gregory, C. W., Lin, Y., Whang, Y. E., Earp, H. S., et al. (2003) · PubMed · Cited by 66
New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
Abramson, V. G., & Arteaga, C. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1947 · Cited by 66
Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells
Dickey, D. D., & Giangrande, P. H. (2015) · Methods · doi:10.1016/j.ymeth.2015.11.020 · Cited by 66
Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression
Menéndez, J. A., Mehmi, I., & Lupu, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3489 · Cited by 65
Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer
Bartlett, J. M. S., Brawley, D., Grigor, K. M., Munro, A. F., Dunne, B., & Edwards, J. (2005) · The Journal of Pathology · doi:10.1002/path.1735 · Cited by 65
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
Dey, N., Williams, C. B., Leyland-Jones, B., & De, P. K. (2015) · PubMed · Cited by 64
Dual HER2-targeted approaches in HER2-positive breast cancer
Ahn, E. R., & Vogel, C. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1781-y · Cited by 64
Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors
Yamamoto, N., Yamada, Y., Fujiwara, Y., Yamada, K., Fujisaka, Y., Shimizu, T., & Tamura, T. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp006 · Cited by 63
Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options
Burnett, J., Körkaya, H., Ouzounova, M., Jiang, H., Conley, S. J., Newman, B. W., Sun, L., Connarn, J. N., Chen, C., Zhang, N., et al. (2015) · Scientific Reports · doi:10.1038/srep15821 · Cited by 64
HER family in cancer progression: From discovery to 2020 and beyond
Kumar, R., George, B., Campbell, M. R., Verma, N., Paul, A. M., Melo-Alvim, C., Ribeiro, L., Pillai, M. R., Costa, L., & Moasser, M. M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.001 · Cited by 66
HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms
Hendriks, B. S., Wiley, H. S., & Lauffenburger, D. A. (2003) · Biophysical Journal · doi:10.1016/s0006-3495(03)74696-7 · Cited by 63
Overcoming Drug Resistance in Patients with Metastatic Breast Cancer
Wong, S. T.-L., & Goodin, S. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.8.954 · Cited by 63
HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches.
Garrido-Castro, A. C., & Felip, E. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.02 · Cited by 63
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64
The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells
Ram, S., Kim, D. Y., Ober, R. J., & Ward, E. S. (2014) · mAbs · doi:10.4161/mabs.29865 · Cited by 62
Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Chen, L., Mooso, B. A., Jathal, M. K., Madhav, A., Johnson, S. D., Spyk, E. N. V., Mikhailova, M., Ripoll, A. Z., Xue, L., Vinall, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1548 · Cited by 61
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors
Garg, A., Quartino, A. L., Li, J., Jin, J., Wada, D., Li, H., Cortés, J., McNally, V. A., Ross, G. A., Visich, J. E., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2560-3 · Cited by 62
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 64
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
Wu, V. S., Kanaya, N., Lo, C., Mortimer, J. E., & Chen, S. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.005 · Cited by 62
Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
Cheng, J. C., Liang, M., Carvalho, M. F., Tigue, N. J., Faggioni, R., Roskos, L. K., & Vainshtein, I. (2020) · Antibodies · doi:10.3390/antib9030049 · Cited by 61
Imaging EGFR and HER2 by PET and SPECT: A Review
Corcoran, E. B., & Hanson, R. N. (2013) · Medicinal Research Reviews · doi:10.1002/med.21299 · Cited by 61
Copine-III interacts with ErbB2 and promotes tumor cell migration
Heinrich, C., Keller, C., Boulay, A., Vecchi, M., Bianchi, M., Sack, R., Lienhard, S., Duss, S., Hofsteenge, J., & Hynes, N. E. (2009) · Oncogene · doi:10.1038/onc.2009.456 · Cited by 61
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets
Shim, H. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.10.063 · Cited by 66
Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways
Yang, Y., Tian, Z., Guo, R., & Ren, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9867595 · Cited by 60
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Raghav, K. P. S., & Moasser, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0283 · Cited by 65
Prolonged EGFR Signaling by ERBB2‐Mediated Sequestration at the Plasma Membrane
Offterdinger, M., & Bastiaens, P. I. H. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00665.x · Cited by 60
Controlled Activation of ErbB1/ErbB2 Heterodimers Promote Invasion of Three-Dimensional Organized Epithelia in an ErbB1-Dependent Manner: Implications for Progression of ErbB2-Overexpressing Tumors
Zhan, L., Xiang, B., & Muthuswamy, S. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4081 · Cited by 60
Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway
Jia, Y., Kodumudi, K. N., Ramamoorthi, G., Basu, A. B., Snyder, C., Wiener, D. A., Pilon‐Thomas, S., Grover, P., Zhang, H., Greene, M. I., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.037 · Cited by 60
Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens
Nahta, R., Shabaya, S., Ozbay, T., & Rowe, D. (2009) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569209790112337 · Cited by 60
Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization
Li, B., Meng, Y., Zheng, L., Zhang, X., Tong, Q., Tan, W., Hu, S., Li, H., Chen, Y., Song, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0657 · Cited by 58
ERBB 3 ( HER 3) is a key sensor in the regulation of ERBB ‐mediated signaling in both low and high ERBB 2 ( HER 2) expressing cancer cells
Choi, B., Fan, X., Deng, H., Zhang, N., & An, Z. (2012) · Cancer Medicine · doi:10.1002/cam4.10 · Cited by 57
Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists
Morshed, A. K. M. H., Azad, S. A., Mia, M. A. R., Uddin, M. F., Ema, T. I., Yeasin, R. B., Srishti, S. A., Sarker, P., Aurthi, R. Y., Jamil, F., et al. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10573-8 · Cited by 58
Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer
de Álava, E., Ocaña, A., Abad, M., Montero, J. C., Esparı́s-Ogando, A., Rodriguez, C. A., Otero, A. P., Hernández, T., Cruz, J. J., & Pandiella, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6850 · Cited by 57
Understanding and circumventing resistance to anticancer monoclonal antibodies
Reslan, L., Dalle, S., & Dumontet, C. (2009) · mAbs · doi:10.4161/mabs.1.3.8292 · Cited by 57
Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Isakoff, S. J., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6679 · Cited by 57
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Gandullo‐Sánchez, L., Capone, E., Ocaña, A., Iacobelli, S., Sala, G., & Pandiella, A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911498 · Cited by 56
Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms
Hollmén, M., Määttä, J. A., Bald, L. N., Sliwkowski, M. X., & Elenius, K. (2009) · Oncogene · doi:10.1038/onc.2008.481 · Cited by 56
Self-citation
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
Rubinson, D. A., Höchster, H. S., Ryan, D. P., Wolpin, B. M., McCleary, N. J., Abrams, T. A., Chan, J. A.-W., Iqbal, S., Lenz, H. J., Lim, D. W., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9956-5 · Cited by 56
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
Wong, D. J. L., & Hurvitz, S. A. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.08.13 · Cited by 56
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Gaborit, N., Lindzen, M., & Yarden, Y. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1102809 · Cited by 56
Anti‐HER‐3 MAbs inhibit HER‐3‐mediated signaling in breast cancer cell lines resistant to anti‐HER‐2 antibodies
van der Horst, E. H., Murgia, M., Treder, M., & Ullrich, A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20867 · Cited by 56
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
Oliveras‐Ferraros, C., Cufí, S., Queralt, B., Vázquez‐Martín, A., Martı́n-Castillo, B., Llorens, R., Bosch‐Barrera, J., Brunet, J., & Menéndez, J. A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.103 · Cited by 55
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
Mullen, P., Cameron, D., Hasmann, M., Smyth, J. F., & Langdon, S. P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0401 · Cited by 55
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
Maadi, H., Nami, B., Tong, J., Li, G., & Wang, Z. (2018) · BMC Cancer · doi:10.1186/s12885-018-4143-x · Cited by 47
Prostate cancer: a dynamic illness with shifting targets
Shaffer, D. R., & Scher, H. I. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01138-0 · Cited by 55
Self-citation
Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance
Russo, R. I. C., Béguelin, W., Flaqué, M. C. D., Proietti, C. J., Venturutti, L., Galigniana, N. M., Tkach, M., Guzmán, P., Roa, J. C., O’Brien, N. A., et al. (2014) · Oncogene · doi:10.1038/onc.2014.272 · Cited by 54
DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction
Chen, X., Liu, P., Wang, Q., Li, Y., Li, F., Fu, H., Zhu, J., Chen, Z., Zhu, W., Xie, C., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.012 · Cited by 55
Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients
Attard, G., & Bono, J. S. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0943 · Cited by 53
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
Gradishar, W. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt217 · Cited by 53

Authors: Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., Scher, H. I., & Sliwkowski, M. X.
Affiliations: Cedars-Sinai Medical Center (US)
Genentech (US)
Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Sliwkowski, Mark X
ORCID: Agus, David B
Scher, Howard I
Sliwkowski, Mark X
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2002-08
Volume: 2
Issue: 2
Pages: 127-137
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/s1535-6108(02)00097-1
OpenAlex: W2014457594
Cited by: 873
References: 83
Citations by year: 2026: 2 · 2025: 10 · 2024: 21 · 2023: 38 · 2022: 21 · 2021: 21 · 2020: 28 · 2019: 29 · 2018: 27 · 2017: 24 · 2016: 38 · 2015: 48 · 2014: 69 · 2013: 59 · 2012: 51
FWCI: 16.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 4003 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: PepsiCo
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: ERBB2, HER2, HER3, neuregulin-1, ErbB receptor family, breast cancer, prostate cancer, tumor growth inhibition, tyrosine kinase inhibitors
MeSH terms: Androgens, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Cell Division, Female, Humans, Ligands, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Binding, RNA, Messenger, Time Factors, Transplantation, Heterologous, Tumor Cells, Cultured, Signal Transduction, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Neuregulin-1, Receptor, ErbB-3, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks